Getting a prescription is not always the same as getting access to treatment. For patients prescribed specialty medications or other complex therapies, the path between a healthcare provider’s treatment decision and the start of therapy can include insurance verification, prior authorization, coverage restrictions, documentation requests, appeals, and questions about out-of-pocket

Serva Health will be exhibiting at DPHARM 2026, taking place September 15 and 16 at the Sheraton Boston. Now in its 16th year, DPHARM brings together more than 1,000 clinical research executives, innovators, patient voices, and technology leaders to explore how clinical trials can become faster, simpler, more accessible, and

Why complex case management and access matters more now For commercial teams, access is no longer a simple sequence of benefits verification, prior authorization, and first dispense. The hardest cases are the ones where patients face multiple barriers at once: restrictive coverage rules, high out-of-pocket costs, specialty pharmacy routing, therapy

For brand, patient services, and market access leaders, affordability support is no longer a niche add-on. Public data indicate that more than 9 million U.S. adults ages 18 to 64 did not take medications as prescribed in 2021 because of cost, while out-of-pocket spending on prescription drugs rose 4.8% to

Rare disease clinical trial support is becoming a core operational capability, not an optional add-on. In rare disease studies, the same constraints appear repeatedly: very small and geographically dispersed populations, heterogeneous disease expression, limited natural history data, difficult endpoint selection, and a high risk that even minor operational friction will